Janine Makaronidis

Dr. Janine Makaronidis


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2020 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
JMJanine Makaronidis
Janine Makaronidis
JMJessica Mok
Jessica Mok
NBNyaladzi Balogun
Nyaladzi Balogun
CMCormac G. Magee
Cormac G. Magee
RORumana Z. Omar
Rumana Z. Omar
RBRachel L. Batterham
Rachel L. Batterham
Loss of smell and taste are commonly reported symptoms associated with coronavirus disease 2019 (COVID-19); however, the seroprevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in people with acute loss of smell and/or taste is unknown. The study aimed to determine the seroprevalence of SARS-CoV-2 antibodies in a community-based population with acute loss of smell and/or taste and to compare the frequency of COVID-19 associated symptoms in participants with and without SARS-CoV-2 antibodies. It also evaluated whether smell or taste loss are indicative of COVID-19 infection. Text messages, sent via primary care centers in London, United Kingdom, invited people with loss of smell and/or taste in the preceding month, to participate. Recruitment took place between 23 April 2020 and 14 May 2020. A total of 590 participants enrolled via a web-based platform and responded to questions about loss of smell and taste and other COVID-19–related symptoms. Mean age was 39.4 years (SD ± 12.0) and 69.1% (n = 392) of participants were female. A total of 567 (96.1%) had a telemedicine consultation during which their COVID-19–related symptoms were verified and a lateral flow immunoassay test that detected SARS-CoV-2 immunoglobulin G (IgG) and immunoglobulin M (IgM) antibodies was undertaken under medical supervision. A total of 77.6% of 567 participants with acute smell and/or taste loss had SARS-CoV-2 antibodies; of these, 39.8% (n = 175) had neither cough nor fever. New loss of smell was more prevalent in participants with SARS-CoV-2 antibodies, compared with those without antibodies (93.4% versus 78.7%, p < 0.001), whereas taste loss was equally prevalent (90.2% versus 89.0%, p = 0.738). Seropositivity for SARS-CoV-2 was 3 times more likely in participants with smell loss (OR 2.86; 95% CI 1.27–6.36; p < 0.001) compared with those with taste loss. The limitations of this study are the lack of a general population control group, the self-reported nature of the smell and taste changes, and the fact our methodology does not take into account the possibility that a population subset may not seroconvert to develop SARS-CoV-2 antibodies post-COVID-19. Our findings suggest that recent loss of smell is a highly specific COVID-19 symptom and should be considered more generally in guiding case isolation, testing, and treatment of COVID-19. ClinicalTrials.gov NCT04377815

23 July 2024 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
FJFriedrich C Jassil
Friedrich C Jassil
MPMaria Papageorgiou
Maria Papageorgiou
EMEmily Mackay
Emily Mackay
ACAlisia Carnemolla
Alisia Carnemolla
HKHelen Kingett
Helen Kingett
RBRachel L. Batterham
Rachel L. Batterham
Context There are limited comparative studies between one-anastomosis gastric bypass (OAGB) vs Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG) on body composition and musculoskeletal health. Objective To compare changes in body composition, areal bone mineral density (aBMD), muscle strength, and physical function in the first year following OAGB, RYGB, and SG within a UK-based healthcare setting. Methods This is a secondary analysis of the BARI-LIFESTYLE trial in 119 adults (77% women; mean ± SD age 45.9 ± 10.3 years; body mass index 43.6 ± 5.5 kg/m2) who underwent OAGB (n = 19), RYGB (n = 39), and SG (n = 61). Body composition and aBMD by dual energy x-ray absorptiometry, handgrip strength, sit to stand (STS) test and 6-minute walking test (6MWT) were assessed presurgery and at 12 months postsurgery. Results OAGB, RYGB, and SG exhibited similar reductions in body weight, body fat, and lean mass (within-group comparisons, P < .001). All surgery types were associated with reductions in aBMD at the total hip, femoral neck, and lumbar spine, which were more pronounced after OAGB and RYGB than after SG (all P < .03), though there was no difference between OAGB and RYGB. Despite reductions in absolute handgrip strength, relative handgrip strength, STS test, and 6MWT improved postsurgery (all P < .02), with no differences by surgical procedure. Conclusion OAGB, RYGB, and SG resulted in comparable weight loss, changes in body composition and improvements in relative muscle strength and physical function. OAGB and RYGB, compared with SG, led to greater BMD reductions at clinically relevant sites. Future long-term studies should explore whether these BMD reductions translate into a greater fracture risk.

31 October 2024 in touchREVIEWS in Endocrinology
Verified
Journal Article
Open access
PDF file
SQSulmaaz Qamar
Sulmaaz Qamar
RMRitwika Mallik
Ritwika Mallik
JMJanine Makaronidis
Janine Makaronidis
Disruption of the hypothalamic circuits controlling body weight and appetite caused by mutations in the genes encoding leptin, LEPR, POMC and MC4R can lead to

22 May 2026 in Nature Medicine
Verified
Journal Article
Open access
CSChloe Stanley
Chloe Stanley
RMRitwika Mallik
Ritwika Mallik
NHNausheen Hamid
Nausheen Hamid
FJFriedrich C. Jassil
Friedrich C. Jassil
VRVictoria Reuven
Victoria Reuven
JMJanine Makaronidis
Janine Makaronidis
A suboptimal clinical response after metabolic and bariatric surgery (MBS) is common and carries considerable health concerns. Here a double-blinded, randomized (1:1), placebo-controlled trial using semaglutide 2.4 mg weekly (BARI-STEP) recruited adult participants at least 1 year after gastric bypass or sleeve gastrectomy with a suboptimal clinical response, defined as less than 20% weight loss from surgery. This was an adjunct to lifestyle intervention with a 500-kcal daily energy deficit. The primary outcome was percentage weight loss after 68-week treatment on an intention-to-treat analysis. Seventy participants (mean (s.d.) age = 47.3 (10.3) years, 58 (82.9%) female and 12 (17.1%) male) were randomized to receive 2.4 mg semaglutide ( n = 35) or placebo ( n = 35). The intention-to-treat sample included 63 participants. Estimated change in mean (s.d.) percentage weight loss from baseline to week 68 was −18.0 (9.2) with semaglutide 2.4 mg ( n = 34) versus +0.4 (7.0) with placebo ( n = 29). The mean adjusted treatment difference in percentage body weight change for semaglutide 2.4 mg versus placebo was −19.18 (95% confidence interval −23.4 to −14.8; P < 0.001). Adverse events (AEs) were consistent with the known safety and tolerability profile of semaglutide, with no new safety concerns for the post-bariatric population. There were eight serious AEs, one suspected unexpected serious adverse reaction and no treatment-related deaths. BARI-STEP demonstrates that in people with a suboptimal clinical response after MBS, semaglutide results in substantial and clinically significant body weight reduction along with improvement in metabolic parameters and quality of life, compared to placebo. These findings suggest that semaglutide 2.4 mg is a safe and effective treatment option for this patient population. ClinicalTrials.gov: NCT05073835 .

6 November 2025 in Clinical Medicine
Verified
Journal Article
Open access
EDEbo Dadey
Ebo Dadey
TLTiong Yeng Lim
Tiong Yeng Lim
JMJanine Makaronidis
Janine Makaronidis
Type 2 diabetes mellitus (T2D) and metabolic dysfunction-associated steatotic liver disease (MASLD), formerly termed non-alcoholic fatty liver disease (NAFLD), are increasingly prevalent conditions that are closely associated. The shared pathophysiology of insulin resistance, chronic inflammation and increased lipid deposition means that there is a bidirectional relationship between the two conditions. MASLD is now a leading cause of cirrhosis and hepatocellular carcinoma (HCC) and has a high prevalence in patients with T2D. This review explores the synergy between MASLD and T2D, while also outlining the diagnostic approach and management of T2D in the context of MASLD. Management involves lifestyle intervention, optimisation of cardiometabolic risk factors and multidisciplinary team involvement. We evaluate the use of antidiabetic medication such as SGLT-2 inhibitors and GLP-1 receptor agonists. Early identification of MASLD can help guide treatment and reduce the risk of progression to liver cirrhosis in high-risk patients.

14 August 2022 in Internal and Emergency Medicine
Verified
Journal Article
Open access
PDF file
JMJanine Makaronidis
Janine Makaronidis
APAndrea Pucci
Andrea Pucci
MAMarco Adamo
Marco Adamo
AJAndrew Jenkinson
Andrew Jenkinson
MEMohamed Elkalaawy
Mohamed Elkalaawy
RBRachel Louise Batterham
Rachel Louise Batterham
‘Hedonic hunger’ indicates the desire to consume food in the absence of an energy requirement. Hedonic hunger can be investigated using the validated Power of Food Scale (PFS). Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG) are currently the most effective treatment options for severe obesity. Following RYGB, hedonic hunger diminishes, which may contribute to sustained weight loss. There are no data examining the effect of SG on hedonic hunger. We prospectively evaluated hedonic hunger using PFS in patients with severe obesity prior to and 6 months after SG (n = 95) or RYGB (n = 44) and investigated the procedure-specific relationship between percentage weight loss (%WL) and hedonic hunger. Anthropometric data were collected at baseline after 6 months, 12 months and 24 months post-operatively. PFS contains 15 items grouped into 3 domains considering when food is: available (FA), present (FP), tasted (FT) and a total score (TS). At 6 months, a significant reduction was seen in all categories post-SG (p < 0.0001) and in TS (p = 0.003), FA (p = 0.0006) and FP (p = 0.0007) post-RYGB. A significantly larger reduction in FP scores was seen post-SG (p = 0.01). Post-SG, a significant correlation with 6-month %WL was noted for changes in FP (p = 0.03) and TS (p = 0.03). Post-SG changes in FP and TS predicted 24-month %WL. Post-RYGB significant correlations were seen between 6-month %WL and dFA (p = 0.04) and dFP (p = 0.03). Changes in FA, FP and TS were predictive of 12-month %WL. HH is reduced following both SG and RYGB with a greater reduction following SG and is related to post-operative %WL. PFS may have a role as a predictive tool for post-operative outcomes following SG and RYGB.